Jane Street’s Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant IBER.U Stock Holding History

Jane Street’s Portfolio IBER.U Stock Details IBER.U Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-57,472	Closed	-$573K	–	10475
2022 Q4	$573K	Sell	57,472 -11,707	-17%	-$117K	﹤0.01%	5889
2022 Q3	$685K	Buy	69,179 +12,040	+21%	+$119K	﹤0.01%	6103
2022 Q2	$560K	Buy	57,139 +594	+1%	+$5.86K	﹤0.01%	6521
2022 Q1	$554K	Hold	56,545	–	–	﹤0.01%	7275
2021 Q4	$567K	Sell	56,545 -9	-0%	-$90	﹤0.01%	7025
2021 Q3	$565K	Buy	56,554 +9	+0%	+$90	﹤0.01%	7055
2021 Q2	$568K	Buy	56,545 +6,545	+13%	+$65.5K	﹤0.01%	7003
2021 Q1	$493K	Buy	+50,000	New	+$500K	﹤0.01%	6831

Jane Street's IBER.U Position: Q1 2023 in Review

Jane Street sold out of Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) in Q1 2023, closing a stake of 57,472 shares — an estimated $573K sold.

Jane Street first reported a position in IBER.U in Q1 2021 and held it in 8 quarters. The position peaked at $685K in Q3 2022. 0 funds tracked by Wall St. Rank hold IBER.U as of Q1 2023.

Jane Street reported no remaining Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position as of Q1 2023 after selling out during the quarter.
Jane Street sold 57,472 Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant shares in Q1 2023, an estimated $573K.
Jane Street first reported a position in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant in Q1 2021 and held it in 8 quarters.
Jane Street's Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position peaked at $685K in Q3 2022.
0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant as of Q1 2023.

Based on Jane Street's 13F filing for Q1 2023, filed 16 May 2023.